128 related articles for article (PubMed ID: 24641103)
21. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
[TBL] [Abstract][Full Text] [Related]
22. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
[TBL] [Abstract][Full Text] [Related]
23. Rational design and synthesis of 2-(1
Im D; Jun J; Baek J; Kim H; Kang D; Bae H; Cho H; Hah JM
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):472-486. PubMed ID: 35067150
[TBL] [Abstract][Full Text] [Related]
24. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK; Grundler R; Peschel C; Duyster J
Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
[TBL] [Abstract][Full Text] [Related]
25. ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells.
Scholl S; Müller R; Clement JH; Loncarevic IF; Böhmer FD; Höffken K
Leuk Res; 2006 May; 30(5):633-42. PubMed ID: 16473406
[TBL] [Abstract][Full Text] [Related]
26. Identification of pyrrolo[2,3-d]pyrimidines as potent HCK and FLT3-ITD dual inhibitors.
Koda Y; Kikuzato K; Mikuni J; Tanaka A; Yuki H; Honma T; Tomabechi Y; Kukimoto-Niino M; Shirouzu M; Shirai F; Koyama H
Bioorg Med Chem Lett; 2017 Nov; 27(22):4994-4998. PubMed ID: 29037944
[TBL] [Abstract][Full Text] [Related]
27. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
Xu B; Zhao Y; Wang X; Gong P; Ge W
Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
[TBL] [Abstract][Full Text] [Related]
28. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
Marhäll A; Heidel F; Fischer T; Rönnstrand L
Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of sorafenib in FLT3-driven leukemic cells.
Auclair D; Miller D; Yatsula V; Pickett W; Carter C; Chang Y; Zhang X; Wilkie D; Burd A; Shi H; Rocks S; Gedrich R; Abriola L; Vasavada H; Lynch M; Dumas J; Trail PA; Wilhelm SM
Leukemia; 2007 Mar; 21(3):439-45. PubMed ID: 17205056
[TBL] [Abstract][Full Text] [Related]
30. Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.
Sun D; Yang Y; Lyu J; Zhou W; Song W; Zhao Z; Chen Z; Xu Y; Li H
J Med Chem; 2016 Jul; 59(13):6187-200. PubMed ID: 27266526
[TBL] [Abstract][Full Text] [Related]
31. Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML.
Wang A; Wu H; Chen C; Hu C; Qi Z; Wang W; Yu K; Liu X; Zou F; Zhao Z; Wu J; Liu J; Liu F; Wang L; Stone RM; Galinksy IA; Griffin JD; Zhang S; Weisberg EL; Liu J; Liu Q
Oncotarget; 2016 May; 7(20):29131-42. PubMed ID: 27074558
[TBL] [Abstract][Full Text] [Related]
32. Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia.
Diab S; Abdelaziz AM; Li P; Teo T; Basnet SKC; Noll B; Rahaman MH; Lu J; Hou J; Yu M; Le BT; Albrecht H; Milne RW; Wang S
Eur J Med Chem; 2017 Oct; 139():762-772. PubMed ID: 28863357
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core.
Xu J; Ong EHQ; Hill J; Chen A; Chai CLL
Bioorg Med Chem; 2014 Dec; 22(23):6625-6637. PubMed ID: 25456387
[TBL] [Abstract][Full Text] [Related]
34. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
[TBL] [Abstract][Full Text] [Related]
35. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
Seedhouse CH; Hunter HM; Lloyd-Lewis B; Massip AM; Pallis M; Carter GI; Grundy M; Shang S; Russell NH
Leukemia; 2006 Dec; 20(12):2130-6. PubMed ID: 17066094
[TBL] [Abstract][Full Text] [Related]
36. Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
Smith AM; Dun MD; Lee EM; Harrison C; Kahl R; Flanagan H; Panicker N; Mashkani B; Don AS; Morris J; Toop H; Lock RB; Powell JA; Thomas D; Guthridge MA; Moore A; Ashman LK; Skelding KA; Enjeti A; Verrills NM
Oncotarget; 2016 Jul; 7(30):47465-47478. PubMed ID: 27329844
[TBL] [Abstract][Full Text] [Related]
37. Structural modifications at the 6-position of thieno[2,3-d]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia.
Kim H; Lee C; Yang JS; Choi S; Park CH; Kang JS; Oh SJ; Yun J; Kim MH; Han G
Eur J Med Chem; 2016 Sep; 120():74-85. PubMed ID: 27187860
[TBL] [Abstract][Full Text] [Related]
38. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
[TBL] [Abstract][Full Text] [Related]
39. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
40. Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer.
Shi X; Li H; Shi A; Yao H; Ke K; Dong C; Zhu Y; Qin Y; Ding Y; He YH; Liu X; Li L; Lei L; Hai Q; Chen W; Leung KS; Wong MH; Kung HF; Lin MC
Oncol Rep; 2018 Sep; 40(3):1592-1600. PubMed ID: 29956794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
